# REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

> **NCT05353166** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** REGN5381
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05353166
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-30
- **Primary completion:** 2025-06-02
- **Final completion:** 2025-06-02
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05353166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05353166, "REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05353166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*